In order to study in detail how germline polymorphisms and acquired somatic events could potentially interact to cause TKI resistance in CML, we generated and characterized genome-edited K562 clones, either with or without the BIM deletion polymorphism, that were rendered resistant to imatinib. This evidence concerns the gene BCL2L11 and chronic myelogenous leukemia, BCR-ABL1 positive.